Controlled Substances Market is projected to record a modest expansion at 4% CAGR through 2028.

Worldwide sales of the controlled substances closed in on a valuation of US$ 67,000 Mn in 2018, and are projected to record a Y-o-Y growth at 3.5% in 2019, according to a new Fact.MR study. The study opines that depressants and stimulants have been top-selling class of drugs in the controlled substances market, however gains from marijuana are expected to record over 2X faster growth than all the other controlled substances in 2019 and beyond.

Approval of medical marijuana has been on a significant uptick in various states of the US, trailed by the legalization in Canada for both recreational and medicinal use recently. This has tremendously contributed to the popularity of cannabis stocks, alongside efforts of leading controlled substance manufacturers toward eliminating legal barriers and attracting investor interest. The study estimates marijuana sales in 2019 to record a Y-o-Y growth at 9.3% over 2018.

“The Schedule of Controlled Substances currently positions marijuana in Schedule 1 – the most restrictive one reserved for “high potential for abuse,” “lack of accepted safety” and “no accepted medical use” drugs. Federal scheduling of marijuana has been a key concern among producers and medical patients alike, despite legalization of cannabis in the US and Canada. The US Drug Enforcement Administration has recently removed cannabidiol from Schedule 1, post-FDA approval of non-synthetic, cannabis-derived medicine. Marijuana businesses have cheered the DEA’s action, as it alludes the beginning of regulatory relaxation to the cannabis industry,” according to a lead analyst at Fact.MR.

Get Sample Copy With Impact Analysis Of COVID-19 Of Market Report –https://www.factmr.com/connectus/sample?flag=S&rep_id=2032

Controlled Substances  Market – Scope of Report:

A latest publication by Fact.MR on the global Controlled Substances  market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the market.

The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, and opportunities in the market.

The principal aim of the study is to present exclusive information about how the market will perform during the forecast period of 2018-2028.

Important indicators for the successful growth of the Controlled Substances  market are presented in this comprehensive report, which include Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described in an exhaustive way in Fact.MR’s study.

This research study can support readers to know the demand for Controlled Substances  supplements, and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in Controlled Substances , including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the market.

Insights and wisdom presented in this Fact.MR study can be leveraged by shareholders in the market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Pain Management Remains Leading Application of Controlled Substances

The study opines that pain management will continue to account for over one-fourth share of the controlled substances market in 2018. Several regulatory norms being implemented in the prescription of controlled substances for pain management, such as in Georgia, Michigan, and Florida, have further triggered the preference and adoption of controlled substances to manage and treat chronic as well as acute pain. Attention deficit hyperactivity disorder (ADHD), and anxiety are other medical conditions wherein controlled substances are expected to witness promising future prospects, according to the study.

The entrance of pharmaceutical giants in the cannabis sector of Canada alludes the next significant trend in the controlled substances industry, offering additional credibility to the sector. Although the pharmaceutical part of the expression involves the missing link, an ongoing trend of M&A and entrance of these legacy industries is poised in 2019 and the foreseeable future. There has been a drought in direct investments from the pharmaceutical industries in the licensed medical marijuana producers, it is highly likely that the trend would change, as the US witnesses the federal legalization of cannabis. Big pharmaceutical companies that eye collaborations and partnerships with cannabis producers having competitive differentiation circling their R&D initiatives, commercialization efforts, and clinical trial programs, are likely to witness significant revenue generation in the near future.

Get Customization on this Report for Specific Research Solutions:- https://www.factmr.com/connectus/sample?flag=RC&rep_id=2032

Report benefits & key questions answered

• Post covid consumer spending on Controlled Substances : the report also highlights the change in the buying behavior of consumers and shifts in purchasing power, post covid-19. This information will assist the businesses to plan their production and marketing strategies.
• Controlled Substances demand outlook: the market intelligence study reports highlights the factor propelling the demand for Controlled Substances . As per the study, the demand for Controlled Substances will grow through 2029.
• Controlled Substances historical volume analysis: Fact.MR survey report provides insights into the sales registered over the last forecast year 2016 to 2018 and create estimates regarding the sales performance for 2018-2028.
• Controlled Substances consumption by demographics: the report provides consumption by demographics analysis to assist the market players in designing their expansion strategies on the basis of consumption pattern of the customers.

Controlled Substances  Market Segmentations:

• By Drug Class

  • Opioids
    • Codeine
    • Morphine
    • Fentanyl
    • Meperidine
    • Methadone
    • Oxycodone
    • Others
  • Stimulants
    • Amphetamine
    • Methylphenidate
    • Dextroamphetamine
    • Methamphetamine
    • Others
  • Depressants
    • Barbiturates
    • Benzodiazepines
  • Marijuana
    • Medical Marijuana
    • Recreational Marijuana

• By Application

  • Attention-Deficit/Hyperactivity Disorder (ADHD)
  • Pain Management
  • Depression
  • Seizure
  • Anxiety
  • Sleep Disorders
  • Cough Suppression
  • Others

• By Distribution Channel

  • Institutional Sale
    • Hospitals
    • Clinics
    • Rehabilitation Centers
  • Retail Sales
    • Retail Pharmacies
    • E- Commerce/Mail Order Pharmacies

For in-depth competitive analysis, Buy Now – https://www.factmr.com/checkout/2032

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of fortune 1,000 companies trust us for making their most critical decisions. We have offices in us and dublin, whereas our global headquarter is in dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our usp is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com